Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics has announced the pricing of its initial public offering (IPO) of 9,000,000 shares at $8.00 per share, aiming for gross proceeds of $72 million. Trading on the Nasdaq Global Market under the ticker CADL is set to commence on July 27, 2021, with the offering expected to close on July 29, 2021. The underwriters also hold a 30-day option to acquire an additional 1,350,000 shares. Candel focuses on developing oncolytic viral immunotherapies to treat cancer.